XML 59 R28.htm IDEA: XBRL DOCUMENT v3.25.2
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 16. COMMITMENTS AND CONTINGENCIES

 

Agreement with CenExel

 

On August 1, 2024, the Company signed an agreement with CenExel to perform a method comparison clinical study as part of the Company’s FDA 510(k) clinical study plan. As a part of the agreement, the Company is committed to pay $381,204 on completion of certain milestones. As of June 30, 2025, $89,007 remains payable under the agreement, which is accrued within current liabilities in the accompanying consolidated balance sheets within accounts payable and accrued expenses.

 

Legal Proceedings

 

From time to time, the Company may become a party to various legal proceedings arising in the ordinary course of business. Based on information currently available, the Company is not involved in any pending or threatened legal proceedings that it believes could reasonably be expected to have a material adverse effect on its financial condition, results of operations or liquidity. However, legal matters are inherently uncertain, and the Company cannot guarantee that the outcome of any potential legal matter will be favorable to the Company.